Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melvin J Yu

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Chemical Information and Modeling|March 11, 2011
Natural product-like virtual libraries: recursive atom-based enumerationMelvin J Yu
Journal of Cheminformatics|April 19, 2013
Druggable chemical space and enumerative combinatoricsMelvin J Yu
Journal of Chemical Information and Modeling|July 13, 2010
Predicting total clearance in humans from chemical structureMelvin J Yu
Journal of Cheminformatics|November 29, 2012
Simulating the drug discovery pipeline: a Monte Carlo approachMelvin J Yu
Bioorganic & Medicinal Chemistry Letters|November 13, 2012
Atom-based enumeration: new eribulin analogues with low susceptibility to P-glycoprotein-mediated drug effluxMelvin J Yu, Wanjun Zheng, Karen Tendyke
Natural Product Reports|July 31, 2013
From micrograms to grams: scale-up synthesis of eribulin mesylateMelvin J Yu, Wanjun Zheng, Boris M Seletsky
Anticancer Research|May 18, 2012
Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditionsMurray J Towle, Kenichi Nomoto, Makoto Asano, et al.
Cancer Research|August 18, 2004
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389Galina Kuznetsov, Murray J Towle, Hongsheng Cheng, et al.
Cancer Research|December 4, 2010
Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditionsMurray J Towle, Kathleen A Salvato, Bruce F Wels, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 2011
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibilitySridhar Narayan, Eric M Carlson, Hongsheng Cheng, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Chemical Information and Modeling|March 11, 2011
Natural product-like virtual libraries: recursive atom-based enumerationMelvin J Yu
Journal of Cheminformatics|April 19, 2013
Druggable chemical space and enumerative combinatoricsMelvin J Yu
Journal of Chemical Information and Modeling|July 13, 2010
Predicting total clearance in humans from chemical structureMelvin J Yu
Journal of Cheminformatics|November 29, 2012
Simulating the drug discovery pipeline: a Monte Carlo approachMelvin J Yu
Bioorganic & Medicinal Chemistry Letters|November 13, 2012
Atom-based enumeration: new eribulin analogues with low susceptibility to P-glycoprotein-mediated drug effluxMelvin J Yu, Wanjun Zheng, Karen Tendyke
Natural Product Reports|July 31, 2013
From micrograms to grams: scale-up synthesis of eribulin mesylateMelvin J Yu, Wanjun Zheng, Boris M Seletsky
Anticancer Research|May 18, 2012
Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditionsMurray J Towle, Kenichi Nomoto, Makoto Asano, et al.
Cancer Research|August 18, 2004
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389Galina Kuznetsov, Murray J Towle, Hongsheng Cheng, et al.
Cancer Research|December 4, 2010
Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditionsMurray J Towle, Kathleen A Salvato, Bruce F Wels, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 2011
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibilitySridhar Narayan, Eric M Carlson, Hongsheng Cheng, et al.
Pageof 2